Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms PRELUDE
- Sponsors Ipsen
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 27 Oct 2017 Status changed from recruiting to discontinued.
- 29 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.